Home・Список акций・ImmunityBio Inc

ImmunityBio Inc

Закрыт

СекторЗдравоохранение

7.31 0.69

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

7.18

Макс.

7.48

Ключевые показатели
By Trading Economics
Доход	-571M -633M
Продажи	5.9M 44M
Прибыль на акцию	-0.08
Рентабельность продаж	-1,431.439
Сотрудники	684
EBITDA	-569M -600M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+79.31% upside

Дивиденды
By Acuity
Следующий отчет о доходах	2 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-293M 7.5B
Предыдущая цена открытия	6.62
Предыдущая цена закрытия	7.31

Новостные настроения

By Acuity

50%

156 / 340 Рейтинг в Healthcare

ImmunityBio Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

5 авг. 2026 г., 19:26 UTC

Immunitybio Inc's shares are higher today amid positive market sentiment. The stock is recovering from earlier weakness despite remaining below its 20-day moving average.

4 авг. 2026 г., 23:46 UTC

Immunitybio Inc. shares are trading roughly flat in after-market hours. The asset remains significantly below its 20-day moving average.

3 авг. 2026 г., 23:21 UTC

Immunitybio Inc shares rose in after-market trading, settling higher since Monday's close. The stock remains below its 20-day moving average.

1 авг. 2026 г., 00:02 UTC

Immunitybio Inc shares are higher in after-market trading, reflecting a notable increase since Friday's close amid broader market dynamics.

31 июл. 2026 г., 23:06 UTC

Immunitybio Inc's shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

30 июл. 2026 г., 19:29 UTC

Immunitybio Inc is trading higher, recovering from an earlier drop. The stock has rebounded significantly since Wednesday's close, despite six consecutive lower daily closes.

29 июл. 2026 г., 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

28 июл. 2026 г., 20:06 UTC

News

ImmunityBio Inc is under investigation for potential wrongdoing, contributing to its decline today. Shares remain lower since Monday's close, marking six consecutive sessions of losses.

27 июл. 2026 г., 19:16 UTC

Immunitybio Inc. shares are lower, continuing a four-session decline amid broader market pressures and a significant drop in oil prices.

24 июл. 2026 г., 23:06 UTC

Immunitybio Inc shares are higher in after-market hours following Friday's close, settling with a cumulative increase after earlier gains. No specific news was identified.

23 июл. 2026 г., 09:16 UTC

Immunitybio Inc shares are higher in pre-market hours, continuing an upward trend since Wednesday. This movement occurs amid broader market pressures from disappointing tech earnings.

22 июл. 2026 г., 19:11 UTC

Immunitybio Inc's shares are lower today, diverging from recent gains. The stock is seeing unusually high trading volume amid rising crude oil prices.

21 июл. 2026 г., 18:06 UTC

Immunitybio Inc is trading higher during Tuesday's session amid positive market sentiment. No specific company news was identified to explain the movement.

20 июл. 2026 г., 23:46 UTC

Immunitybio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Сравнение c конкурентами

Изменение цены

ImmunityBio Inc Прогноз

Целевая цена

By TipRanks

79.31% рост

Прогноз на 12 месяцев

Средняя 13 USD 79.31%

Максимум 15 USD

Минимум 12 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для ImmunityBio Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

3 ratings

Покупка

Удержание

Продажа

Основано на мнении 3 аналитиков, присваивавших рейтинги акциям ImmunityBio Inc – Данные за последние 3 месяца.

Настроения

By Acuity

156 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.